SAN FRANCISCO—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital allocation strategy heading into 2026.
read moreIn a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at $587 million for the year, a 4% decline from its 2024 figure of $612 million. More: JPM26: Apellis
read moreWith Ebvallo’s latest U.S. rejection, Atara Biotherapeutics and its partner Pierre Fabre Pharmaceuticals are accusing the FDA of pulling an about-face. More: Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub Source: fierce
read more
Authorisation marks major step in European preparedness against ricin More: Fabentech secures French approval for Ricimed antidote Source: News
read moreCellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after inking a long-term lease for space that will house manufacturing and offices in the Netherlands. More: Cellares to expand cell therapy factory-in-a-box to
read more
Data shows potential route to overcoming resistance in aggressive colorectal tumours More: Oxford Drug Design reports major in vivo milestone for novel cancer therapy Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals